Gozellix was also evaluated in an open-label study (PSMA-BCR ... who gain enhanced access to state-of-the-art 68 Ga PSMA-PET imaging.” ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD open-label ...